Adaptimmune is a fully integrated cell therapy company focused on developing engineered cell therapies with the potential to redefine treatment of solid tumors.
Joined July 2015
- Tweets 2,107
- Following 296
- Followers 3,893
- Likes 200
1,004 Photos and videos
7 Oct 2024
What a milestone! With the first commercial product order accepted, $ADAP looks forward to bringing this newly FDA-approved cell therapy to more patients in need. adaptimmune.com
#CellTherapy #Biotech #Innovation
15
5
33
5,971
2 Aug 2024
ICYMI: $ADAP received @US_FDA accelerated approval for the first engineered cell therapy for the treatment of a solid tumor cancer. Announcement here: bit.ly/3AkpUJu
#celltherapy #biotech #oncology
6
15
65
9,468
30 May 2024
#BreakingNews @GalapagosGlobal and
$ADAP sign clinical collaboration and exclusive option to license agreement for TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications. bit.ly/4aMsKnc
A live webcast will be held on Friday, May 31st at 8am ET. Live webcast and replay can be accessed at bit.ly/3Rv6Jmn
5
15
44
10,450
Adaptimmune retweeted
6 Mar 2024
Today $ADAP reported financial results for Q4 and full year ended Dec. 31, 2023, and provided a business update on the progress made in establishing our sarcoma franchise. Release: bit.ly/48GMojA Call replay: bit.ly/4a0DfmZ #biotech #celltherapy #sarcoma
1
3
15
5,597
27 Feb 2024
Please join us in welcoming back Cintia Piccina as $ADAP Chief Commercial Officer! Effective March 18, 2024, Cintia returns to lead a rapidly expanding commercial team as it prepares for the launch of afami-cel which, once approved, will be the first engineered TCR T-cell therapy on the market targeting solid tumors. #celltherapy #leadership
1
3
15
2,909
31 Jan 2024
BREAKING NEWS: FDA accepts $ADAP application for our investigational engineered T-cell therapy for the treatment of #synovialsarcoma with priority review. Press release here: bit.ly/3HGZ4fd #biotech #fda
3
13
58
7,218
11 Jan 2024
$ADAP ICYMI – replay (bit.ly/3NWDyGI) of our presentation at #JPMHC24 – where we outlined our near- and long-term value proposition with our wholly owned cell therapy pipeline. Email investor.relations@adaptimmune.com to schedule time with management.
3
10
2,459
11 Jan 2024
$ADAP CEO Adrian Rawcliffe spoke today at #JPMHC24 about the company’s sarcoma franchise and work from discovery to delivery of cell therapies with the potential to redefine the treatment of solid tumors. #celltherapy #oncology #biotechnology
2
4
10
2,989
4 Jan 2024
Our CEO, Adrian Rawcliffe, will present Adaptimmune’s 2024 plans at the J.P. Morgan Healthcare Conference next Thursday, January 11th from 8:15 to 8:55 a.m. PST.
Release here: bit.ly/3H2Srnj. The presentation can be accessed live from the Westin, San Francisco or at the webcast and replay link here: bit.ly/3TOBnZI.
1
5
11
4,984
6 Dec 2023
$ADAP today announced the completion of the rolling Biologics License Application (BLA) to the FDA for an investigational engineered T-cell therapy for the treatment of advanced #SynovialSarcoma! The first ever BLA to be submitted for an engineered T-cell therapy for solid tumors. See release here: bit.ly/46QTMrv
5
11
43
5,669
29 Nov 2023
Today, we announced completion of the transfer of the IND for letetresgene autoluecel (lete-cel) from GSK to $ADAP for the pivotal IGNYTE-ESO (NCT03967223) clinical trial. Data from this trial frame lete-cel as a synergistic product to afami-cel within our cell therapy pipeline. For more information see release: bit.ly/3RkSuAA
1
3
7
2,782
8 Nov 2023
ICYMI: $ADAP today announced selection of ADP-600 as a clinical candidate for its best-in-class PRAME strategy. See release for details: bit.ly/3QNFnYA
6
1
3
1,420
8 Nov 2023
#News: Today, $ADAP provided its Q3 2023 financial and business update. Release and details for replay can be accessed here: bit.ly/3MAUsKy
#earnings #celltherapy #biotechnology
2
4
1,084
31 Oct 2023
$ADAP and @bvantine1 to present SPEARHEAD-1 trial long-term outcomes data at the #CTOS 2023 Annual Meeting. 39% of patients who received ADAP treatment had clinical responses. 70% of people with advanced disease who responded to ADAP treatment are alive 2 years post-treatment. See link bit.ly/45Y0dZs
2
3
9
2,871
23 Oct 2023
$ADAP today presented clinical and translational
data from the Ph 1 SURPASS clinical trial at #ESMO23. Data show a 50% response rate in 26 patients with ovarian, urothelial, and head & neck cancers and 75% response rate in these three cancers in patients who received three or fewer prior lines of therapy. See release for more details: bit.ly/46VMcwi
3
5
12
2,909